Tafenoquine treatment of Plasmodium vivax malaria: Suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

by Pamela L. St Jean, Zhengyu Xue, Nick Carter, Gavin C.K.W. Koh, Stephan Duparc, Maxine Taylor, Claire Beaumont, Alejandro Llanos-Cuentas, Ronnatrai Rueangweerayut, Srivicha Krudsood, Justin A. Green, Justin P. Rubio
Published 2018

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria

by Pamela L. St Jean, Gavin C.K.W. Koh, John J. Breton, Fe E.J. Espino, Tran T. Hien, Srivicha Krudsood, Marcus V.G. Lacerda, Alejandro Llanos-Cuentas, Chanthap Lon, Rezika Mohammed, Chayadol S. Namaik-Larp, Dhelio B. Pereira, David L. Saunders, Ivan D. Velez, Daniel Yilma, Maria F. Villegas, Stephan Duparc, Justin A. Green
Published 2020